A new pathologic scoring system — that accurately assesses how much lung tumor is left after a patient receives presurgical cancer treatments such as immunotherapy or chemotherapy — can be used to predict survival. This new research is led by investigators at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center and the Mark Foundation Center for Advanced Genomics and Imaging at the Johns Hopkins University.
